HC Wainwright Analysts Give Diffusion Pharmaceuticals (DFFN) a $1.00 Price Target
Separately, ValuEngine upgraded Diffusion Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, November 1st.
Shares of NASDAQ DFFN opened at $0.32 on Thursday. The firm has a market capitalization of $15.96 million, a P/E ratio of -0.28 and a beta of -1.43. Diffusion Pharmaceuticals has a one year low of $0.30 and a one year high of $2.08.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.